← Back to patent-cliff list
CAS 94594-90-8
(3aS)-8,8-Dimethylhexahydro-3a,6-methano-2lambda6-2lambda6,1-benzothiazole-2,2(3H)-dione
Codes：(I)101438-14-a
Application context (from source-drug indications)
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(3aS)-8,8-Dimethylhexahydro-3a,6-methano-2lambda6-2lambda6,1-benzothiazole-2,2(3H)-dione→2-((4-methoxybenzyl)oxy)acetyl chloride→(1S,5S,7R)-4-{2-[(4-methoxyphenyl)methoxy]acetyl}-10,10-dimethyl-3-thia-4-azatricyclo[5.2.1.0(1,5)]decane-3,3-dione→N-[(1Z)-Phenylmethylidene]benzamide→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-2-(benzoyloxy)-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-15-yl (2R,4S,5R)-3-benzoyl-2-(4-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylate→N-[(1S,2R)-3-[(1S,5S,7R)-10,10-dimethyl-3,3-dioxo-3-thia-4-azatricyclo[5.2.1.0(1,5)]decan-4-yl]-2-[(4-methoxyphenyl)methoxy]-3-oxo-1-phenylpropyl]benzamide→(1S,5S,7R)-4-{[(4S,5R)-3-benzoyl-2-(4-methoxyphenyl)-4-phenyl-1,3-oxazolidin-5-yl]carbonyl}-10,10-dimethyl-3-thia-4-azatricyclo[5.2.1.0(1,5)]decane-3,3-dione→(4S,5R)-3-Benzoyl-2-(4-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylic acid→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.